Vertex Pharmaceuticals has demonstrated promising clinical data for its off-the-shelf stem cell therapy aimed at type 1 diabetes, with 10 out of 12 patients stopping insulin injections a year after treatment. The therapy, known as zimislecel or VX-880, involves lab-grown stem cells that differentiate into insulin-producing islet cells. Updated results, presented at the American Diabetes Association conference and published in the New England Journal of Medicine, revealed sustained insulin production without severe hypoglycemia episodes. This therapy marks a significant advance in regenerative treatment for diabetes, offering potential for long-term glucose regulation.